{"version":"1.0","provider_name":"Times South Africa","provider_url":"https:\/\/timessouthafrica.com","author_name":"TSA","author_url":"https:\/\/timessouthafrica.com\/author\/tsa\/","title":"Adagio Therapeutics annonce une r\u00e9duction de l\u2019activit\u00e9 neutralisante in vitro de l\u2019ADG20 contre le variant Omicron du virus SARS-CoV-2 - Times South Africa","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"l9QmavYQWM\"><a href=\"https:\/\/timessouthafrica.com\/adagio-therapeutics-annonce-une-reduction-de-lactivite-neutralisante-in-vitro-de-ladg20-contre-le-variant-omicron-du-virus-sars-cov-2\/\">Adagio Therapeutics annonce une r\u00e9duction de l\u2019activit\u00e9 neutralisante in vitro de l\u2019ADG20 contre le variant Omicron du virus SARS-CoV-2<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/timessouthafrica.com\/adagio-therapeutics-annonce-une-reduction-de-lactivite-neutralisante-in-vitro-de-ladg20-contre-le-variant-omicron-du-virus-sars-cov-2\/embed\/#?secret=l9QmavYQWM\" width=\"600\" height=\"338\" title=\"&#8220;Adagio Therapeutics annonce une r\u00e9duction de l\u2019activit\u00e9 neutralisante in vitro de l\u2019ADG20 contre le variant Omicron du virus SARS-CoV-2&#8221; &#8212; Times South Africa\" data-secret=\"l9QmavYQWM\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Les donn\u00e9es in vitro pr\u00e9c\u00e9demment rapport\u00e9es d\u00e9montrant que les mutations Omicron individuelles n\u2019\u00e9taient pas associ\u00e9es \u00e0 l\u2019\u00e9chappement de l\u2019ADG20 ne se traduisent pas par des essais Omicron sur des souches authentiques et des pseudovirus WALTHAM, Mass., 14 d\u00e9c. 2021 (GLOBE NEWSWIRE) \u2014 Adagio Therapeutics, Inc. (Nasdaq\u00a0: ADGI), une soci\u00e9t\u00e9 biopharmaceutique au stade clinique ax\u00e9e sur [\u2026]"}